Andere Sprachen Pacific Shuanglin Bio-pharmacy Co., LTD

Aktien

000403

CNE000000F14

000403

Schlusskurs Shenzhen S.E. Andere Börsenplätze 00:00:00 28.06.2024			% 5 Tage	% 1. Jan.
26.66 ^CNY	+0.11%		-4.58%	-2.13%

27.05.	PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD : Bewertung von Morgan Stanley zum Kaufen erhalten	ZM
23.05.	Pacific Shuanglin Bio-pharmacy's Einheit erhält grünes Licht für die Erprobung von intravenösem menschlichem Immunglobulin	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pacific Shuanglin Bio-pharmacy Co., LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024	24.06.
Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin	23.05.
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023	22.05.
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License	09.05.
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	26.04.
Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4%	15.04.
Pacific Shuanglin Bio-pharmacy's Profit Seen More Than Doubling in Q1; Shares Up 3%	15.04.
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	12.04.
Pacific Shuanglin Bio-pharmacy Co., LTD announced a financing transaction	23.02.
Pacific Shuanglin Bio-pharmacy Unit Gets Nod to Trial Human Coagulation Factor IX	06.11.
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Board Appointments	26.10.23
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	18.10.23
Pacific Shuanglin Bio-pharmacy Obtains Another Blood Collection License	22.09.23
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23.08.23
Pacific Shuanglin Bio-pharmacy Obtains Blood Plasma Collection License	08.08.23
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	21.07.23
Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.	20.07.23
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Dividend Implementation on A Shares for the Year 2022, Payable on July 20, 2023	14.07.23
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	03.07.23
Pacific Shuanglin Bio-pharmacy's Unit Gets Permit to Operate Two Plasma Hubs	26.05.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pacific Shuanglin Bio-pharmacy Co., LTD

Aktien

000403

CNE000000F14

000403

Andere Sprachen

Filter